The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II, multicenter, single-arm clinical trial of response-adapted definitive radiotherapy and cemiplimab-rwlc immunotherapy for locally advanced, unresectable cutaneous squamous cell carcinoma: RAMPART.
 
Christopher Barker
Consulting or Advisory Role - Regeneron
Research Funding - Alpha TAU Medical (Inst); Amgen (Inst); Elekta (Inst); EMD Serono/Merck (Inst); PSI (Inst); Regeneron (Inst)
 
Ryan Lanning
No Relationships to Disclose
 
Shlomo Koyfman
Honoraria - Varian Medical Systems
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Castle Biosciences; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Regeneron
Research Funding - Bristol-Myers Squibb (Inst); Castle Biosciences (Inst); Merck Sharp & Dohme (Inst)
Other Relationship - UpToDate
 
Jay Liao
Research Funding - Genentech (Inst); Matrix Biomed (Inst)
 
Upendra Parvathaneni
No Relationships to Disclose
 
Bhisham Chera
Stock and Other Ownership Interests - Naveris
Patents, Royalties, Other Intellectual Property - Naveris
 
Thomas Galloway
Honoraria - UpToDate
Research Funding - Cardinal Health
 
Kaveh Zakeri
No Relationships to Disclose
 
Yao Yu
Research Funding - EMD Serono (Inst)
Patents, Royalties, Other Intellectual Property - Springer
 
Linda Chen
No Relationships to Disclose
 
Achraf Shamseddine
No Relationships to Disclose
 
Daphna Gelblum
No Relationships to Disclose
 
Alan Ho
Honoraria - Horizon CME
Consulting or Advisory Role - AffyImmune Therapeutics; Cantor Fitzgerald; Day One Biopharmaceuticals; GlaxoSmithKline; Immunome; InhibRx; Johnson & Johnson/Janssen; National Cancer Institute; Pyxis; Remix Therapeutics; Rgenta Therapeutics; Takeda
Speakers' Bureau - Miami Cancer Research Center; Mt. Sinai; New York University (NYU); Northwell Health; Physicans' Education Resource
Research Funding - Astellas Pharma; AstraZeneca; Avacta Life Sciences; Ayala Pharmaceuticals; Bayer; Bayer; BioAtla; Bristol-Myers Squibb; Daiichi; Eisai; Genentech/Roche; Hookipa Biotech; Kura Oncology; Merck; Novartis; OncC4; Poseida; Remix Therapeutics; Rgenta; TILT Biotherapeutics; Verastem
Patents, Royalties, Other Intellectual Property - LESIONAL DOSIMETRY METHODS FOR TAILORING TARGETED RADIOTHERAPY IN
Travel, Accommodations, Expenses - Hookipa Pharma; Lepu Biopharma; Remix Therapeutics
Other Relationship - Hookipa Biotech; Lepu Biopharma
(OPTIONAL) Uncompensated Relationships - Alliance for Clinical Trials in Oncology; HPV Cancer Alliance; International Thyroid Oncology Group
 
Nancy Lee
No Relationships to Disclose
 
Zhigang Zhang
No Relationships to Disclose
 
Lara Dunn
Consulting or Advisory Role - Regeneron
Research Funding - Imvaq Therapeutics; Regeneron; Replimune; Seagan